Those with a two-fold change are hsa-miR-92a (logFC −1.08); hsa-miR-19a (logFC −1.06); hsa-miR-17 (logFC −1.05); hsa-miR-135b (logFC −1.4); hsa-miR-20a (logFC −1.07); hsa-miR-20a* (logFC −1.07) and hsa-miR-9* (logFC −1.08), and all are involved in important KEGG pathways such as pathways in cancer, colorectal pathways, bladder cancer and TFG-beta signaling pathway by targeting genes like NRAS, APC, RUNX1, BCL2, MAPK9, CCND1, SMAD4, HIF1A, MYC, CDKN1A, VEGFA, PTEN, TGFBR2, and JAK1 (Tables S9 and S10). The gene discussed is SMAD4; the disease is urinary bladder cancer.